Navigation Links
Catalent Expert to Discuss the Importance of Formulation to Benefit Diabetes Patients at NLS Days
Date:9/4/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Rob Harris, Ph.D., Director, Science & Technology will present at the upcoming Nordic Life Science Days (NLS Days) conference, being held at the MalmöMässan Exhibition & Congress Center, Malmö, Sweden on Sept. 10-12, 2019.

On Thursday, Sept. 12 at 8:45 a.m., Dr. Harris will participate in the “Digitalization for the Benefit of the Diabetes Patient” panel session. The panelists will present different perspectives of how diabetes patients can benefit from recent digital advancements including viewpoints from the pharmaceutical industry, digitalization experts, and patient support groups. Dr. Harris will discuss the importance of formulation to overcome drug factors such as poor solubility and patient factors, including pill fatigue from the burden of multiple daily doses. He will also explain ways in which formulators can work with device developers on complex drug products to improve patient outcomes.

Ahead of NLS Days, on Tuesday, Sept. 10, Catalent will host a workshop, titled “Setting up your Drug for Clinical Success: Strategies and Considerations from Discovery to Clinic”. The day-long event will include expert speakers from Catalent and the wider pharmaceutical industry, and will focus on the key considerations for transitioning a molecule from discovery through to clinical studies. For more information, please visit: catalentmalmo.com.

Dr. Harris has over 35 years’ experience in the pharmaceutical industry. He started his career in technical support roles with R.P. Scherer, Warner Lambert and Glaxo Wellcome, before spending time in academia as a Research Fellow at the University of Manchester. For the past 15 years, Dr. Harris has worked in the pharmaceutical contract development and manufacturing sector, holding senior technical roles with Quay Pharma, Capsugel, Penn Pharma and Juniper Pharma Services (now part of Catalent). He has overseen the development of numerous new drug candidates for clinical evaluation and maintains a keen interest in technologies for enhancing oral bioavailability for challenging compounds, and the development of pediatric medicines.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard(at)nepr(dot)agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 30 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_expert_to_discuss_the_importance_of_formulation_to_benefit_diabetes_patients_at_nls_days/prweb16543980.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
2. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
3. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
4. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
5. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
6. Catalent Executives to Present on Clinical Trial Supply Management and Optimizing Product Development at Upcoming BioPharma Asia Conference
7. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
8. Cold Chain Experts Modality Solutions Recognized as an Inc. Verified Company
9. Lauren Bronich-Hall, Senior Quality Management Expert, Joins NDA Partners as an Expert Consultant
10. Process Characterization Expert Dr. Philippe Cini to Moderate Session at ISPE
11. October is Non-GMO Month – Industry Expert David Carter Available for Comment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2020)... ... January 09, 2020 , ... A new report from ... vendor qualification process, a critical element of clinical trial set up and execution. ... vendor qualification process creates delays in initiation in 7% of clinical trials for ...
(Date:1/8/2020)... , ... January 08, 2020 , ... ... wire composites that can achieve specific properties for use in harsh environments inside ... Wire combines up to three metals or alloys to achieve specific properties ...
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... Vuja De ... cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM ... and CEO of Vuja De said, “We are delighted to welcome Chand and Lee ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... second cohort of emerging biosciences ventures invited to participate in the annual program. ... develop fundable business plans and a professional network. All startups will receive an ...
Breaking Biology Technology:
(Date:2/13/2020)... ... February 13, 2020 , ... Strategic ... Report: The Laboratory Analytical & Life Science Instrumentation Industry. The report will be ... standard of market intelligence for the $70 billion laboratory market for analytical and ...
(Date:2/11/2020)... ... February 11, 2020 , ... The ... medical device accelerator in Port Covington, Baltimore. The newly formed company is developing ... addressed to manage increased demand for home dialysis treatments. The start-up company will ...
(Date:2/5/2020)... , ... February 04, 2020 , ... ... Office (USPTO) issued the company a second patent related to proprietary liquid crystal ... Allowance compliments another patent from the USPTO issued on December 3, 2019. Together, ...
Breaking Biology News(10 mins):